Oncopeptides Overview
- Founded
- 2000

- Status
- Public
- Employees
- 160

- Stock Symbol
- ONCO

- Share Price
- $0.84
- (As of Wednesday Closing)
Oncopeptides General Information
Description
Oncopeptides AB is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Contact Information
- Luntmakargatan 46, 7th floor
- 111 37 Stockholm
- Sweden
Oncopeptides Timeline
Oncopeptides Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.84 | $0.84 | $0.40 - $14.04 | $63M | 75.3M | 1.47M | -$1.89 |
Oncopeptides Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | (1,264) | (6,332) | 1,265,978 | 637,490 |
Revenue | 13,671 | 13,775 | 0 | 0 |
EBITDA | (132,851) | (162,968) | (171,021) | (77,693) |
Net Income | (146,651) | (166,551) | (172,955) | (78,312) |
Total Assets | 28,167 | 48,551 | 115,415 | 106,259 |
Total Debt | 0 | 1,568 | 2,359 | 1,593 |
Oncopeptides Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.
Request a free trialOncopeptides Comparisons
Industry
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialOncopeptides Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
000000000 00000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 000.00 | 0000000000 0 | 000.00 |
Oncopeptides Patents
Oncopeptides Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020259142-A1 | Novel formulations comprising melflufen | Pending | 17-Apr-2019 | 000000000 | |
CA-3133886-A1 | Novel formulations comprising melflufen | Pending | 17-Apr-2019 | 000000000 | |
CA-3116198-A1 | Compounds containing deuterium | Pending | 18-Oct-2018 | 00000000000 | |
EP-3866931-A1 | Compounds containing deuterium | Pending | 18-Oct-2018 | 00000000000 | |
AU-2019362389-A1 | Compounds containing deuterium | Pending | 18-Oct-2018 | C07K5/06191 |
Oncopeptides Executive Team (20)
Oncopeptides Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Brian Stuglik | Self | Board Member | 000 0000 |
Cecilia Wennborg | Self | Board Member | 000 0000 |
Jarl Jungnelius Ph.D | Self | Board Member | 000 0000 |
Jennifer Jackson Ph.D | Self | Board Member | 000 0000 |
Jonas Brambeck Ph.D | Industrifonden | Board Member | 000 0000 |
Oncopeptides Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOncopeptides Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.
Request a free trial